{"nctId":"NCT02678351","briefTitle":"68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery","startDateStruct":{"date":"2016-04-18","type":"ACTUAL"},"conditions":["Stage II Prostate Adenocarcinoma","Stage III Prostate Adenocarcinoma"],"count":74,"armGroups":[{"label":"68Ga-PSMA PET/MRI","type":"EXPERIMENTAL","interventionNames":["Drug: 68Ga-PSMA-11","Procedure: Magnetic resonance imaging (MRI)","Procedure: Positron Emission Tomography (PET)"]}],"interventions":[{"name":"68Ga-PSMA-11","otherNames":["68-gallium prostate-specific membrane antigen 11 positron emission tomography/magnetic resonance imaging","HBED CC PSMA","DFKZ 11","Heidelberg compound"]},{"name":"Magnetic resonance imaging (MRI)","otherNames":["Nuclear magnetic resonance imaging","MRI imaging","NMR Imaging","NMRI"]},{"name":"Positron Emission Tomography (PET)","otherNames":["PET scan","Positron Emission Tomography Scan","Proton magnetic resonance spectroscopic imaging"]}],"eligibilityModule":{"eligibilityCriteria":"INCLUSION CRITERIA\n\n* Biopsy-proven prostate adenocarcinoma\n* Planned prostatectomy with lymph node dissection\n* Intermediate- to high-risk disease (as determined by elevated prostate-specific antigen (PSA) \\[PSA \\> 10\\], T stage \\[T2b or greater\\], Gleason score \\[Gleason score \\> 6\\] or other risk factors)\n* Karnofsky performance status of â‰¥ 50 \\[or Eastern Cooperative Oncology Group (ECOG)/World Health Organization (WHO) equivalent\\]\n* Diagnostic CT or MRI performed within 90 days of the research PET\n* Able to provide written consent\n\nExCLUSION CRITERIA\n\n* Patients not capable of getting PET study due to weight, claustrophobia, or inability to lay still for the duration of the exam\n* Neoadjuvant chemotherapy or radiation therapy prior to prostatectomy, including focal ablation techniques (HiFu)\n* Androgen deprivation therapy or other neoadjuvant treatments prior to PET imaging and surgery\n* Metallic implants (contraindicated for MRI)","healthyVolunteers":false,"sex":"MALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"68Ga-PSMA-11 PET Detection of Prostate Cancer Metastasized to Lymph Nodes","description":"68-gallium (68Ga)-prostate-specific membrane antigen (PSMA) positron emission tomography/magnetic resonance imaging (PET/MRI) will be used to detect regional nodal and distant metastases in participants with intermediate and high-risk prostate cancer scheduled to undergo prostatectomy with lymph node dissection. The data will be analyzed by imaging interpretation. Each participant will be interpreted as either positive or negative for the presence of metastatic disease by 68Ga-PSMA PET/MRI, as assessed by imaging interpretation. The outcome will be expressed as the number of participants with metastatic disease, as identified by PET/MRI, a number without dispersion.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null}]}]}]},{"type":"SECONDARY","title":"Histopathologic Detection of Prostate Cancer Metastasized to Lymph Nodes","description":"Participants that undergo prostatectomy will be evaluated for prostate cancer metastasis to the lymph nodes as determined by histopathology. Each participants will be interpreted as either positive or negative for the presence of metastatic disease by histopathology. The outcome will be expressed as the number of participants with metastatic disease, as identified by histopathology, a number without dispersion.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null}]}]}]},{"type":"SECONDARY","title":"Sensitivity of 68Ga-PSMA-11 PET/MRI","description":"68-gallium (68Ga)-prostate-specific membrane antigen (PSMA) positron emission tomography/magnetic resonance imaging (PET/MRI) will be used to detect metastases in participants with intermediate and high-risk prostate cancer scheduled to undergo prostatectomy with lymph node dissection. For participants that undergo both procedures (68Ga-PSMA PET/MRI and prostatectomy), sensitivity of the 68Ga-PSMA PET/MRI detection of metastatic prostate cancer will be determined. For an individual participant, sensitivity means the 2 assessments are in agreement that the participant truly has (ie, true-positive) have the condition being tested for (ie, metastatic prostate cancer). The outcome is reported as the percentage of participants for which the 2 assessments are in agreement that metastatic prostate cancer is detected (true-positive), a number without dispersion.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Specificity of 68Ga-PSMA-11 PET/MRI","description":"68-gallium (68Ga)-prostate-specific membrane antigen (PSMA) positron emission tomography/magnetic resonance imaging (PET/MRI) will be used to detect metastases in participants with intermediate and high-risk prostate cancer scheduled to undergo prostatectomy with lymph node dissection. For participants that undergo both procedures (68Ga-PSMA PET/MRI and prostatectomy), specificity of the 68Ga-PSMA PET/MRI detection of metastatic prostate cancer will be determined. For an individual participant, specificity means the 2 assessments are in agreement that the participant does not (ie, true-negative) have the condition being tested for (ie, metastatic prostate cancer). The outcome is reported as the percentage of participants for which the 2 assessments are in agreement that metastatic prostate cancer is not detected (true-negative), a number without dispersion.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":74},"commonTop":[]}}}